Inovio's DNA Vaccine Found to Be Effective Against Avian Flu
Posted on: Thursday, 17 July 2008, 09:01 CDT
Inovio Biomedical has announced positive pre-clinical results from two proprietary plasmid DNA-based universal influenza vaccine candidates using the company's proprietary electroporation delivery technology and, specifically, a new intradermal device.
In this study, 100% of the immunized mice given a lethal challenge of highly pathogenic H5N1 influenza virus (A/Vietnam/1203/04) survived and showed only minor weight loss.
The DNA vaccine design was based on a different influenza strain (H1N1) than the influenza strain used in the challenge, providing evidence that a universal vaccine based on conserved genes common to multiple strains of seasonal influenza and even potential pandemic influenza may have the possibility to provide widespread protection against such viruses.
In collaboration with Vandalia Research, Inovio also tested the use of fully synthetic linear expressing cassettes to express the same antigens and achieved similar results.
Avtar Dhillon, CEO of Inovio, said: "Only a broad-spectrum influenza DNA vaccine, such as the one we're testing, would have the potential to provide protection against multiple known and unknown influenza strains."
Source: Datamonitor
Related Articles
- Vical Demonstrates Dose-Sparing of Protein-Based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
- VaxInnate Initiates Phase I Clinical Study of M2e Universal Influenza Vaccine
- MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
- Inovio Biomedical Establishes Agreements With National Cancer Institute and International Aids Vaccine Initiative to Conduct Research Using Inovio's DNA Delivery Technology
- MedImmune Licenses Reverse Genetics Technology to CSL for Use in Influenza Vaccine Production
- Vical Vaccine Adjuvant Boosts Immune Response to Influenza Vaccine
- PowderMed to Conduct U.S. Clinical Trial of DNA-Based Annual Influenza Vaccine
- Generex Biotechnology to Present Its Avian Influenza Vaccine Program at DNA Forum in London
- Novavax and Bharat Biotech Announce Strategic Alliance for Pandemic Influenza Vaccine Development
 |
 |
User Comments (0)
RSS Feeds